3 ms·
> But as far as I know there's no clinically proven benefit My impression of US pharma regulation and drug trials is that it would not have been approved if it
by loeg 4y ago
> But as far as I know there's no clinically proven benefit
My impression of US pharma regulation and drug trials is that it would not have been approved if it did not show some benefit over the status quo. I don't know about adderall's clinical trials in particular, though.
- mtlmtlmtlmtl 4y agoI was a little unclear maybe. What I meant was that there's no clinically proven benefit of racemic amphetamine versus dextroamphetamine. Racemic amphetamine is certainly an effective treatment, that's been well proven.
- loeg 4y agoBy “status quo,” I meant dextroamphetamine.
- mtlmtlmtlmtl 4y agoOh I see, my bad! I think I was still in the mindset of thinking adderall pre-existed dexedrine. So I guess I interpreted status quo as meaning amphetamine vs whatever else was available at the time. Interesting little inversion of logic that can happen when two people have diametrically opposed ideas of the order of events.
- loeg 4y agoHah, no worries.
- philwelch 4y agoAdderall was originally formulated and marketed as a diet drug. It had already been approved before it was rebranded and remarketed for ADHD, and the criteria for approving a new on-label use is significant but not as rigorous as approving a new drug. Drugs that are still under a patent have a company with the incentive to go through the expensive approval process while generic drugs lack that. So a wacky mix of amphetamines designed as a diet drug that are still under patent have more corporate backing for that approval process than plain old generic dextroamphetamine, which has been around forever. There’s a similar story with the use of esketamine versus ketamine to treat depression.
- loeg 4y agoAh, thanks for elaborating on the history.